Elan Corp PLC (ELN)

[io_io]

BIIB CEO target: 100k patients on Tysabri by end 2010

Announces Strategic Updates at Investor Meetings

Thursday September 6, 8:00 am ET

Strong Growth Cycle Drives Goal of 15% Top-Line CAGR and 20% Bottom-Line CAGR Through 2010

15 Products in Phase 2 or Beyond to Contribute to Mid-to-Long Term Growth


CAMBRIDGE, Mass.--(BUSINESS WIRE)--In presentations to investors today and over the next week, Biogen Idec (NASDAQ: BIIB - News) CEO James C. Mullen will outline key growth opportunities and review the company's long-range strategic and financial goals. ........ Supplemental information in the form of a slide presentation will also be accessible on the internet at the same location at the time of each presentation and will remain on the Biogen Idec website until at least September 30, 2007.

... Specifically, the company expects its growth to be driven by:

Continued solid performance of AVONEX® (Interferon beta-1a), the world's leading multiple sclerosis treatment;
Expansion of RITUXAN® (rituximab), the world's leading cancer treatment, into autoimmune diseases;
Achieving the milestone of 100,000 patients on TYSABRI® (natalizumab) by year-end 2010; and,
Continued geographic diversification of its revenue base with more than 40% of revenue from its International business by 2010.

"Now that Biogen Idec is more than a year into the reintroduction of TYSABRI in the U.S., and we have launched and gained reimbursement for this important therapy in the major European markets, we are providing greater detail regarding our goals for long-range growth," Mullen said. "Over the near- to mid-term, we expect to see continued strong performances by AVONEX and RITUXAN as well as the emergence of TYSABRI as the world's leading therapy for patients with multiple sclerosis."